These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 30458232)
41. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses. Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943 [TBL] [Abstract][Full Text] [Related]
42. Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo. Rossowska J; Pajtasz-Piasecka E; Szyda A; Krawczenko A; Zietara N; Dus D Oncol Rep; 2009 Jun; 21(6):1539-49. PubMed ID: 19424635 [TBL] [Abstract][Full Text] [Related]
43. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Teitz-Tennenbaum S; Li Q; Rynkiewicz S; Ito F; Davis MA; McGinn CJ; Chang AE Cancer Res; 2003 Dec; 63(23):8466-75. PubMed ID: 14679011 [TBL] [Abstract][Full Text] [Related]
44. Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response. Rossowska J; Pajtasz-Piasecka E; Szyda A; Zietara N; Duś D Folia Histochem Cytobiol; 2007; 45(4):349-55. PubMed ID: 18165174 [TBL] [Abstract][Full Text] [Related]
45. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. Curiel-Lewandrowski C; Mahnke K; Labeur M; Roters B; Schmidt W; Granstein RD; Luger TA; Schwarz T; Grabbe S J Immunol; 1999 Jul; 163(1):174-83. PubMed ID: 10384114 [TBL] [Abstract][Full Text] [Related]
46. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. Furumoto K; Soares L; Engleman EG; Merad M J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076 [TBL] [Abstract][Full Text] [Related]
47. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma. Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873 [TBL] [Abstract][Full Text] [Related]
48. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962 [TBL] [Abstract][Full Text] [Related]
49. Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Hahn T; Alvarez I; Kobie JJ; Ramanathapuram L; Dial S; Fulton A; Besselsen D; Walker E; Akporiaye ET Int J Cancer; 2006 May; 118(9):2220-31. PubMed ID: 16331615 [TBL] [Abstract][Full Text] [Related]
50. [Studies on the enhancement of DC vaccine to mouse Lewis lung cancer by CpG oligonucleotides]. Du YC; Lin P; Zhang J; Lu YR; Ning QZ Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):1-5. PubMed ID: 15771786 [TBL] [Abstract][Full Text] [Related]
51. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide. Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352 [TBL] [Abstract][Full Text] [Related]
52. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene. Murakami T; Tokunaga N; Waku T; Gomi S; Kagawa S; Tanaka N; Fujiwara T Clin Cancer Res; 2004 Jun; 10(11):3871-80. PubMed ID: 15173096 [TBL] [Abstract][Full Text] [Related]
53. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine. Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013 [TBL] [Abstract][Full Text] [Related]
54. Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines. Miguel A; Herrero MJ; Sendra L; Botella R; Algás R; Sánchez M; Aliño SF Cancer Gene Ther; 2013 Oct; 20(10):576-81. PubMed ID: 23969885 [TBL] [Abstract][Full Text] [Related]
55. Comparison of fusion protein and DC vaccine in inhibition of mouse B16F10 melanoma tumor. Zhang Y; Liu X; Wang R; Liu S; Wang Y; Jing L; Louis MDJ; Cao R Biomed Pharmacother; 2018 Jan; 97():784-792. PubMed ID: 29112931 [TBL] [Abstract][Full Text] [Related]
56. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. Chiodoni C; Paglia P; Stoppacciaro A; Rodolfo M; Parenza M; Colombo MP J Exp Med; 1999 Jul; 190(1):125-33. PubMed ID: 10429676 [TBL] [Abstract][Full Text] [Related]
57. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105 [TBL] [Abstract][Full Text] [Related]
58. [Dendritic cells present particulate E7 protein of human papillomavirus and induce strong immunity]. Li J; Gao HQ; Zhao CL; Li LZ; Ji CY; Hou M; Plebaski M Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):932-6. PubMed ID: 15329282 [TBL] [Abstract][Full Text] [Related]
59. [Comparative study on effect of astragulus injection and interleukin-2 in enhancing anti-tumor metastasis action of dendrite cells]. Dong JC; Dong XH Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Mar; 25(3):236-9. PubMed ID: 15842146 [TBL] [Abstract][Full Text] [Related]
60. Imiquimod enhances the potency of an exogenous BM-DC based vaccine against mouse melanoma. Ren S; Wang Q; Zhang Y; Song Y; Dong X; Zhang W; Qin X; Liu M; Yu T Int Immunopharmacol; 2018 Nov; 64():69-77. PubMed ID: 30149266 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]